Hon Kam Lun, Leung Alexander K C, Cheng James W C H, Luk David C K, Leung Agnes S Y, Koh Mark J A
Department of Paediatrics, CUHKMC, The Chinese University of Hong Kong, Hong Kong, China.
Department of Pediatrics, The University of Calgary, The Alberta Children's Hospital, Calgary, Alberta, Canada.
Curr Pediatr Rev. 2024;20(4):478-488. doi: 10.2174/1573396320666230626122135.
Allergic contact dermatitis (ACD) is prevalent among pediatric population, adolescent and young adults. Patients with ACD experience a lot of sociopsychological and qualityof- life (QoL) difficulties. Children and their caregivers alike are vulnerable to the burden of ACD.
We have, in this paper, provided an overview of ACD and discussed common and unusual causes of ACD.
We performed an up-to-date literature review in the English language on "allergic contact dermatitis" PubMed Clinical Queries, using the keywords "allergic contact dermatitis" in August 2022. The search included meta-analyses, randomized controlled trials, clinical trials, casecontrol studies, cohort studies, observational studies, clinical guidelines, case series, case reports, and reviews. The search was restricted to English literature and children.
ACD may be acute or chronic and it affects more than 20% of children and adults with significant quality-of-life impairments. ACD is manifested by varying degrees of cutaneous edema, vesiculation, and erythema. The hypersensitivity reaction is one of the most prevalent forms of immunotoxicity in humans. Localized acute ACD lesions can be managed with high-potency topical steroids; if ACD is severe or extensive, systemic corticosteroid therapy is often required to provide relief within 24 hours. In patients with more severe dermatitis, oral prednisone should be tapered over 2-3 weeks. Rapid discontinuation of corticosteroids can result in rebound dermatitis. Patch testing should be performed if treatment fails and the specific allergen or diagnosis remains unknown.
ACD is common and can be a physically, psychologically, and economically burdensome disease. Diagnosis of ACD is primarily based on history (exposure to an allergen) and physical examination (morphology and location of the eruption). Skin patch test can help determine the causative allergen. Allergen avoidance is the cornerstone of management. Topical mid- or highpotency corticosteroids are the mainstay of treatment for lesions on less than 20% of the body area. Severe cases of ACD may require treatment with systemic corticosteroids.
过敏性接触性皮炎(ACD)在儿童、青少年和年轻成年人中普遍存在。患有ACD的患者会经历许多社会心理和生活质量(QoL)方面的困难。儿童及其照顾者都容易受到ACD负担的影响。
在本文中,我们对ACD进行了概述,并讨论了ACD常见和不常见的病因。
我们于2022年8月在PubMed临床查询中使用关键词“过敏性接触性皮炎”,以英语进行了最新的文献综述。检索内容包括荟萃分析、随机对照试验、临床试验、病例对照研究、队列研究、观察性研究、临床指南、病例系列、病例报告和综述。检索仅限于英语文献和儿童。
ACD可能是急性的或慢性的,它影响超过20%的儿童和成年人,对生活质量有显著损害。ACD表现为不同程度的皮肤水肿、水疱形成和红斑。超敏反应是人类最常见的免疫毒性形式之一。局部急性ACD病变可用高效局部类固醇治疗;如果ACD严重或广泛,通常需要全身用皮质类固醇治疗以在24小时内缓解。对于皮炎更严重的患者,口服泼尼松应在2至3周内逐渐减量。快速停用皮质类固醇会导致反弹性皮炎。如果治疗失败且特定过敏原或诊断仍不明确,应进行斑贴试验。
ACD很常见,可能是一种在身体、心理和经济上造成负担的疾病。ACD的诊断主要基于病史(接触过敏原)和体格检查(皮疹的形态和部位)。皮肤斑贴试验有助于确定致病过敏原。避免接触过敏原是管理的基石。对于体表面积小于20%的病变,局部中效或高效皮质类固醇是主要治疗方法。严重的ACD病例可能需要全身用皮质类固醇治疗。